10-K: NeuroOne Reports Strong Revenue Growth, Reduced Losses in FY2025

NeuroOne Medical Technologies Corporation announced significant product and collaboration revenue growth, leading to a substantial reduction in net loss for the fiscal year ended September 30, 2025, despite ongoing concerns about its ability to continue as a going concern.

Summary

• NeuroOne Medical Technologies Corporation reported a net loss of $3.6 million for the fiscal year ended September 30, 2025, a significant improvement from the $12.3 million net loss in the prior year.
• Product revenue increased to $9.1 million in FY2025 from $3.5 million in FY2024, driven by sales of the higher-margin OneRF Ablation System.
• Collaboration revenue of $3.0 million was recognized in FY2025 from an upfront payment by Zimmer for exclusive distribution rights of the OneRF Ablation System.
• Gross profit percentage improved to 56.5% in FY2025 from 31.3% in FY2024, primarily due to the OneRF Ablation System.
• The company received FDA 510(k) clearance for its OneRF Trigeminal Nerve Ablation System on August 15, 2025, and initiated a limited market release in December 2025.
• Cash and cash equivalents stood at approximately $6.6 million as of September 30, 2025.
• Net cash used in operating activities significantly decreased to $2.8 million in FY2025 from $11.0 million in FY2024.
• The company completed an April 2025 financing, raising approximately $8.2 million in net proceeds through the issuance of 18.4 million common shares at $0.50 per share.
• An accumulated deficit of $78.6 million was reported as of September 30, 2025.
• Management noted substantial doubt about the company's ability to continue as a going concern, though current cash and anticipated revenues are expected to fund operations through September 2026.
• A material weakness in internal controls over financial reporting was identified due to insufficient segregation of duties.

Sentiment

Score: 6

Explanation: The company showed significant financial improvement with reduced losses and strong revenue growth, driven by new product commercialization and strategic partnerships. However, the persistent 'going concern' doubt, Nasdaq delisting risk, and identified material weakness in internal controls temper the overall positive sentiment, indicating continued operational and financial challenges despite progress.

Positives

• Net loss significantly reduced to $3.6 million in FY2025 from $12.3 million in FY2024, indicating improved financial performance.
• Product revenue increased by $5.6 million, reaching $9.1 million in FY2025, a 161% increase year-over-year.
• Gross profit percentage improved substantially to 56.5% in FY2025 from 31.3% in FY2024, driven by higher-margin product sales.
• Secured $3.0 million in collaboration revenue from Zimmer for exclusive distribution rights of the OneRF Ablation System.
• Received FDA 510(k) clearance for the OneRF Trigeminal Nerve Ablation System, expanding the product portfolio and market reach.
• Successfully raised approximately $8.2 million in net proceeds from the April 2025 financing, bolstering liquidity.
• Net cash used in operating activities decreased significantly from $11.0 million in FY2024 to $2.8 million in FY2025.
• The company's existing cash and anticipated revenues are projected to fund operations through September 2026.
• Established an advisory board for the Basivertebral Nerve Ablation (BVNA) development program in October 2025.

Negatives

• The company has incurred significant operating losses since inception, with an accumulated deficit of $78.6 million as of September 30, 2025.
• Management and the independent registered public accounting firm have noted substantial doubt about the company's ability to continue as a going concern.
• Received a Nasdaq minimum bid price notification on May 6, 2025, and was granted an extension until May 4, 2026, to regain compliance, indicating potential delisting risk.
• Identified a material weakness in internal controls over financial reporting due to insufficient segregation of duties, increasing the risk of financial misstatements.
• The company was a victim of a cyber-related crime in January 2023, resulting in a $0.1 million loss that is not expected to be recovered.
• Reliance on Zimmer for commercialization and sales of key products (Evo Cortical, Evo sEEG, OneRF Ablation System) means Zimmer's failure to perform could materially harm the business.
• The company does not anticipate receiving the additional $1.0 million milestone payment from Zimmer related to net sales thresholds for the OneRF Ablation System.
• Future equity or debt financings will likely result in substantial dilution for existing stockholders.

Risks

• Incurred significant operating losses since inception and cannot assure profitability.
• Substantial doubt about the ability to continue as a going concern, requiring additional capital.
• Reliance on Zimmer for commercialization and sales of Evo Cortical, Evo sEEG, and OneRF Ablation System; Zimmer's failure to perform could have a material adverse effect.
• Inability to raise additional capital on acceptable terms or at all, potentially forcing delays, scaling back, or cessation of operations.
• Adverse effects from inflation, increasing overall cost structure.
• Inability to obtain a supply of components and raw material products.
• Dependence on a limited number of third-party suppliers, risking supply disruptions or increased costs.
• Changes in the configuration of technology under development may result in additional costs or delays.
• Inability to successfully develop, receive regulatory clearance/approval for, and commercialize products under development, or significant delays in doing so.
• Failure to secure or retain coverage or adequate reimbursement for products by third-party payors.
• Competition from products that are safer, more effective, less costly, easier to use, or otherwise more attractive.
• Dependence on the partnership with Mayo; termination or lack of success would harm the business.
• Failure to successfully commercialize technology or gain market acceptance.
• Risks associated with outsourced manufacturing, potentially reducing gross margins and affecting operating results.
• Failure of the company or third-party suppliers/manufacturers to comply with FDA good manufacturing practice regulations.
• Potential complications from products that are currently unknown, leading to delayed development, inability to obtain regulatory approval, liability, or lack of adoption.
• Undetected errors or defects in products could harm reputation, decrease market acceptance, or expose the company to product liability claims.
• Significant disruptions in information technology systems, including cyber-related crimes, could adversely affect business.
• Collaborations, in-licensing arrangements, joint ventures, strategic alliances, or partnerships may not result in commercially viable products or significant future revenues.
• Inability to retain key executives and attract, retain, and motivate qualified personnel.
• Uncertainty in protecting intellectual property and proprietary technology, including patent challenges and infringement.
• Extensive governmental regulation and potential adverse regulatory actions.
• Volatility in the price of common stock and potential delisting from Nasdaq due to minimum bid price requirement.
• Material weakness in internal controls over financial reporting due to insufficient segregation of duties.
• Future issuance of shares to raise capital will result in substantial dilution.
• Anti-takeover provisions in corporate documents.
• Reduced reporting requirements as a smaller reporting company may make common stock less attractive to investors.
• No dividends expected in the future.
• Lack of securities or industry analyst coverage.
• Common stock may be subject to penny stock rules.
• Adverse global economic conditions, including inflation, supply chain constraints, and geopolitical conflicts.
• Changes in tax laws or exposure to additional income tax liabilities.
• Risks associated with growing business through acquisitions.
• Increased costs and demands upon management as a public company.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future until higher levels of commercial sales revenue are achieved. Current cash and anticipated product revenues, combined with improved gross margins and forecasted operating expense reductions, are expected to fund operations through September 2026. However, management has noted substantial doubt about the company's ability to continue as a going concern, and securing additional funding through equity or debt financing or collaborations will be necessary. The company aims to expand the use of its commercialized products in the U.S. and internationally, launch the OneRF TN Ablation System, and continue developing percutaneous SCS paddle electrodes and a BVNA system, while also seeking drug delivery partnerships.

Management Comments

• We believe our technology, once developed, will offer an all-in-one solution with diagnostic and therapeutic capabilities.
• Many leading neurologists believe that the limits of todays current technologies are the reason the exact cause of epileptic seizures is not well-determined.
• We believe our technology provides a number of advantages over other commercially available technologies...
• Our goal is to be the global leader in minimally invasive all in one therapies for brain related and other neurological disorders that leverages our thin film electrode technology to be used for recording, monitoring, deep brain and peripheral stimulation and ablation, drug delivery, owning the procedure from diagnosis through treatment.
• Management has noted the existence of substantial doubt about our ability to continue as a going concern.
• We believe its current available cash and cash equivalents coupled with the anticipated increase in product revenues from minimum purchases and improved gross margins under the Zimmer Amendment and forecasted operating expense reductions, will be sufficient to fund the Companys operations through September 2026.
• Our management has concluded that the financial statements included elsewhere in this Annual Report present fairly, in all material respects, our financial position, results of operations and cash flows in conformity with generally accepted accounting principles.

Industry Context

NeuroOne operates in the highly competitive medical technology sector, specifically focusing on neuromodulation and ablation solutions for neurological disorders and pain management. The market for epilepsy diagnosis and treatment is significantly underpenetrated due to the invasiveness and multi-stage nature of current procedures, which NeuroOne aims to address with its "all-in-one" diagnostic and therapeutic technology. The global spinal cord stimulation market is substantial ($2.5-$3 billion), and the basivertebral nerve ablation market is rapidly growing ($100 million/year). The company's thin-film electrode technology and less invasive approaches position it to potentially disrupt these markets, but it faces strong competition from larger, well-established players like Medtronic, Boston Scientific, Abbott, and Stryker, who possess greater financial resources, market recognition, and existing sales forces. The company's strategy to leverage partnerships, like the one with Zimmer, is a common approach for smaller med-tech firms to gain market access and commercialization scale.

Comparison to Industry Standards

• NeuroOne's "all-in-one" OneRF Brain Ablation System is highlighted as the first and only FDA-cleared system capable of nervous tissue ablation using the same Evo sEEG-RF Electrode for both diagnostic and therapeutic applications, differentiating it from competitors like Medtronic, Monteris Medical, and Clearpoint's LITT technology which use MRI-guided laser ablation.
• The OneRF TN Ablation System features a first-of-its-kind multi-contact RF probe for precise localization and tailored ablation, aiming to reduce procedural time and improve patient comfort/safety compared to existing RF ablation systems from Boston Scientific and Avanos.
• The company's SCS solution utilizes a percutaneously-placed thin-film paddle electrode, which is presented as less invasive than existing spinal cord paddle electrodes that are 20 times larger and predominantly implanted by surgeons, potentially opening the market to pain management doctors who currently only implant traditional percutaneous electrodes.
• The BVNA system aims to leverage multi-contact sEEG probes to increase placement flexibility compared to existing cleared BVNA systems from Boston Scientific and Stryker, which are limited to two-contact probes.
• The drug delivery system in development is designed to record brain activity before, during, and after drug delivery with the same device, a capability not present in currently available drug delivery devices from competitors like Clearpoint and Sophysa (CED).
• Automated manufacturing process is cited as a factor making the company's electrode technology cost-competitive and improving reliability and consistency compared to traditional methods.

Corporate Governance

Related Party Transactions

• Warrants to purchase 20,834 shares of common stock issued to a director on the Board of Directors in the August 2024 Private Placement had their exercise price reset to $0.876 per share in April 2025, given a higher floor price provision for that individual, compared to $0.465 for most other PIPE Warrants.

Stakeholder Impact

• Shareholders: Potential for significant dilution from future capital raises; risk of delisting from Nasdaq; improved financial performance (reduced net loss, increased revenue) could positively impact sentiment; material weakness in internal controls could erode confidence.
• Employees: Equity incentive plans (2025 Plan, Inducement Plan) aim to attract and retain qualified personnel; potential impact from "going concern" doubt.
• Customers (Healthcare Providers/Patients): New FDA-cleared products (OneRF TN Ablation System) and products in development offer potentially less invasive and more effective treatment options for neurological disorders and pain management.
• Partners (Zimmer, Mayo, WARF): Continued collaboration with Zimmer for distribution and development; ongoing royalty obligations to WARF and Mayo. Zimmer's performance is critical to commercial success.
• Creditors: "Going concern" doubt raises concerns about the company's ability to meet its financial obligations.

Next Steps

• Expand the use of Evo Cortical, Evo sEEG, and OneRF Brain Ablation System in the United States and begin commercialization in select international markets with Zimmer.
• Continue the limited market release of the OneRF TN Ablation System.
• Continue to develop percutaneous placed paddle electrodes for spinal cord and peripheral stimulation for pain management.
• Facilitate partnerships for drug delivery systems.
• Develop the Basivertebral Nerve Ablation (BVNA) System.
• Explore partnerships with other companies leveraging core technology in cardiovascular, orthopedic, and pain-related indications.
• Monitor common stock closing bid price to regain compliance with Nasdaq's minimum bid price requirement by May 4, 2026.
• Implement remediation measures to address the material weakness in internal controls over financial reporting, including enhancing policies, segregating key functions, and formalizing accounting and business procedures.
• Seek additional funding through public or private equity or debt financing, or through collaborations, to fund operations beyond September 2026.

Key Dates

Recommendation

While NeuroOne has demonstrated significant improvements in its financial performance, including substantial revenue growth and a reduced net loss, and has achieved key regulatory milestones with new product clearances, the persistent "going concern" doubt and the Nasdaq minimum bid price compliance issue present considerable risks. The identified material weakness in internal controls also adds a layer of uncertainty. The company's reliance on its partnership with Zimmer and the need for further capital raises introduce additional dependencies and potential dilution. Given the mix of positive operational momentum and significant financial and regulatory uncertainties, a 'hold' recommendation is appropriate. Investors should monitor the company's progress in addressing its going concern status, Nasdaq listing, and internal control remediation, as well as the commercial success of its newly launched and pipeline products.

Keywords

NeuroOne Medical Technologies, medical technology, neuromodulation, epilepsy, Parkinson's disease, trigeminal neuralgia, chronic pain, deep brain stimulation, ablation system, sEEG electrode, cortical electrode, drug delivery, FDA clearance, Zimmer Biomet, 10-K filing, financial results, going concern, Nasdaq compliance, medical device, biotech